B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Lieping Chen(Yale Cancer Center), Dallas B. Flies(Mayo Clinic in Arizona), Diva R. Salomão(Mayo Clinic in Arizona), Hideto Tamura(Social Insurance Saitama Chuo Hospital), Fumiya Hirano(Mayo Clinic), Karla V. Ballman(Mayo Clinic in Arizona), Stephen G. Voss, Jan L. Kasperbauer(Mayo Clinic), John C. Cheville(Mayo Clinic), Koji Tamada(Yamaguchi University), Wei Lin(Florida Hospital Cancer Institute), Haidong Dong(Mayo Clinic in Arizona)
PubMed
October 1, 2003
Cited by 492
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
|Journal of Clinical Investigation|2015|1.4k